• Type of Event: Q2 and H1 FY27 Earnings Conference Call held post-results announcement.
  • Date and Time: The call was held on Tuesday, November 3, 2026. The specific time was not disclosed in the transcript.
  • Purpose: To discuss the Un-audited Financial Results (Consolidated and Standalone) for the quarter and half year ended September 30, 2026 and to announce a significant corporate action.
  • Timing Relative to Earnings: The call was held after the earnings announcement, as it references disclosures dated October 29, 2026 and November 3, 2026.
  • Management Participants: The management was represented by:
  • Mr. Nirmal Momaya, Managing Director
  • Mr. Santosh Parab, President - Strategy & Global CFO
  • Mr. Pankaj Pandey, Chief Financial Officer
  • Availability of Materials: The transcript of the call is enclosed with the regulatory filing and is also available on the Company's website at https://www.camlinfs.com/investor-relations/home/investorcallrecording. Audio recordings were uploaded to the stock exchange on November 3, 2026.
  • UPSI Statement: The company explicitly stated that discussions were based on publicly available information and that no unpublished price sensitive information (UPSI) was discussed during the interactions.

Financial Period Discussed: The call primarily discussed the Q2 (Quarter ended September 30, 2026) and H1 (Half Year ended September 30, 2026) FY27 results.

Key Financial Highlights & Forward-Looking Statements:

  • Q2 FY27 Performance: Consolidated financial performance was weak. Revenue was not stated as a single figure but broken down by vertical. EBITDA margin was 2.5% for the quarter, down from 3.4% in the previous quarter.
  • Segment-wise Performance:
  • Specialty Ingredients Segment (Blends & Straights): Revenue was ~INR 4,089 million (vs. INR 4,013 million in Q1). EBITDA margin for the segment was 8.04% (vs. 6.35% in Q1).
  • Blends Sub-vertical: Revenue was ~INR 2,970 million (vs. INR 3,086 million in Q1). It holds gross margins of 35-40% and an EBITDA margin of 11-12%.
  • Straights Sub-vertical: Revenue improved to INR 1,109 million (from INR 927 million in Q1). Margins were pressured.
  • Aroma Vertical (Vanillin): Performance was severely impacted. Revenue fell to INR 472 million (from INR 774 million in Q1). Only 358 metric tons of vanillin were sold (ethyl and methyl), down from 580 MT in Q1. The vertical reported an EBITDA margin of -23% due to significant unabsorbed fixed costs (~INR 20 crores/quarter) and low capacity utilization.
  • Diphenol Plant: The diphenol plant has been closed since May 2026 due to exorbitant input costs (phenol prices more than doubled) making it economically untenable. It incurred a cash burn of INR 5 crores in Q2 for maintenance (mothballed status).
  • Liquidity Crisis & Impact: The company cited a severe liquidity crisis impacting operations. This led to the use of channel financing and long outstanding trade payables, which cost an estimated 3-4% of overall cost (~INR 190-200 million/quarter), eroding margins. It also prevented the company from pursuing growth opportunities.
  • Rights Issue: The Board approved a rights issue of INR 250 crores. The draft letter of offer will be filed with stock exchanges imminently. The purpose is to augment working capital, stabilize the working capital cycle, and fund growth. Promoters have committed to subscribing to their share (~48%). The process is expected to be completed by the end of calendar year 2026 or early next year.
  • Management Outlook & Guidance (Post-Liquidity):
  • Q3 FY27 Outlook: Management expects performance to be only a "tad better" than Q2, with minimal margin improvement, as the liquidity from the rights issue will not be received in time.
  • Q4 FY27 Outlook: With the expected liquidity infusion, management targets a significant turnaround: revenue of at least INR 600 crores and an EBITDA margin of ~10% (INR 60+ crores EBITDA). This is expected from margin improvement (saving on channel financing costs), revenue growth in blends (adding ~INR 50 crores revenue at 35% margin), and scaling vanillin sales.
  • Vanillin Scale-up Plan: Management has visibility of 2,500-2,700 tons demand in the US and 1,300-1,500 tons in Europe for the next calendar year. They aim to sell 1,000 MT per quarter in Q4 FY27 (Q1 CY27) at a net realization of \$12-\$12.5/ kg (after distributor margins), contributing ~INR 650-700 million incremental revenue and ~INR 230 million gross margin.
  • Revised FY27 EBITDA: Management acknowledged that the earlier guidance of INR 200 crores EBITDA for FY27 (on ~INR 2,000 cr revenue) will not be achieved due to the weak H1 performance (H1 EBITDA ~INR 10 cr). The turnaround is now projected for Q4.
  • Balance Sheet: Net debt stood at INR 5,380 million, up slightly from INR 5,260 million, largely due to foreign exchange translation. Interest cost was ~INR 163 million for the quarter.

Additional Notes Section

  • The document is the submitted transcript of the earnings conference call, enclosed with the regulatory filing to the exchanges.
  • The transcript contains extensive financial data and management commentary that was discussed during the call.
  • The document includes a detailed question-and-answer session with analysts from firms including InCred Equities, Coheron Wealth, White Pine Investment Management, Phillip Capital, and Sanghavi Family Office.